Our research is focused on understanding the biological events involved in the inflammatory response to gluten in human participants with coeliac disease and gluten-related disorders. We employ a range of immunological techniques to study this response and collaborate with scientists in the fields of cereal science, structural biology, protein chemistry, microbiome and omics technologies, as well as clinicians and public health specialists.

Key areas of interest are:

  • developing tools that detect and measure the gluten-specific T cell to improve coeliac disease diagnosis and monitoring of clinical trials
  • investigating how gluten triggers adverse symptoms by assessing its acute effects in the blood and intestine of people with coeliac disease and gluten sensitivity
  • testing novel coeliac therapies to establish proof-of-concept and efficacy
  • establish the significance of oats immune responses on safety in coeliac disease
  • assessing the role of environmental factors (e.g. diet, microbiome) on coeliac disease development (as part of the ENDIA study) and in non-responsive coeliac disease
  • understanding the molecular and mutational basis for the development of refractory coeliac disease and lymphoma
  • improving clinical tools and pathways to promote timely and cost-effective diagnosis, monitoring and management of coeliac disease.

We work closely with industry partners to ensure our research can be translated to the clinic, and the involvement of the national patient association organisation Coeliac Australia helps keep our goals relevant to the needs of people with coeliac disease.


Selected publications from A/Prof Jason Tye-Din

Tye-Din JA, Daveson AJM, Goel G, Goldstein KE, Hand HL, Neff KM, Popp A, Taavela J, Maki M, Isola J, Williams LJ, Truitt KE, Anderson RP; RESET CeD Study Group. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. Lancet Gastroenterol Hepatol. 2023 Mar 7:S2468-1253(22)00428-9. PMID: 36898393

Kamal N, Tsardakas Renhuldt N, Bentzer J, Gundlach H, Haberer G, Juhász A, Lux T, Bose U, Tye-Din JA, Lang D, van Gessel N, Reski R, Fu YB, Spégel P, Ceplitis A, Himmelbach A, Waters AJ, Bekele WA, Colgrave ML, Hansson M, Stein N, Mayer KFX, Jellen EN, Maughan PJ, Tinker NA, Mascher M, Olsson O, Spannagl M, Sirijovski N. The mosaic oat genome gives insights into a uniquely healthy cereal crop. Nature. 2022 Jun;606(7912):113-119. PMID: 35585233

Kim ML, Hardy MY, Edgington-Mitchell LE, Ramarathinam SH, Chung SZ, Russell AK, Currie I, Sleebs BE, Purcell AW, Tye-Din JA, Wicks IP. Hydroxychloroquine inhibits the mitochondrial antioxidant system in activated T cells. iScience. 2021 Nov 25;24(12):103509. PMID: 34934928

Anderson RP, Goel G, Hardy MY, Russell AK, Wang S, Szymczak E, Zhang R, Goldstein KE, Neff K, Truitt KE, Williams LJ, Dzuris JL, Tye-Din JA. Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease. Clin Exp Immunol. 2021 Jun;204(3):321-334. PMID: 33469922

Tye-Din JA, Daveson AJM, Goldstein KE, Hand HL, Neff KM, Goel G, Williams LJ, Truitt KE, Anderson RP; RESET CeD Study Group. Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. BMC Med. 2020 Nov 26;18(1):362. PMID: 33239013

Tye-Din JA, Daveson AJM, Ee HC, Goel G, MacDougall J, Acaster S, Goldstein KE, Dzuris JL, Neff KM, Truitt KE, Anderson RP. Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Aliment Pharmacol Ther. 2019 Oct;50(8):901-910. PMID: 31483515

Goel G, Tye-Din JA, Qiao SW, Russell AK, Mayassi T, Ciszewski C, Sarna VK, Wang S, Goldstein KE, Dzuris JL, Williams LJ, Xavier RJ, Lundin KEA, Jabri B, Sollid LM, Anderson RP. Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Science Advances 2019 Aug 7;5(8):eaaw7756. PMID: 31457091

Hardy MY, Russell AK, Pizzey C, Jones CM, Watson KA, La Gruta NL, Cameron DJ, Tye-Din JA. Characterisation of clinical and immune reactivity to barley and rye ingestion in children with coeliac disease. Gut. 2019 May;69(5):830-840. PMID: 31462555

Caminero A, Galipeau HJ, McCarville JL, Johnston CW, Bernier SP, Russell AK, Jury J, Herran AR, Casqueiro J, Tye-Din JA, Surette MG, Magarvey NA, Schuppan D, Verdu EF. Duodenal bacteria from patients with celiac disease and healthy subjects distinctly affect gluten breakdown and immunogenicity. Gastroenterology. 2016 Jun 30. pii: S0016-5085(16)34713-8. PMID: 27373514

Hardy MY, Girardin A, Pizzey C, Cameron DJ, Watson KA, Picascia S, Auricchio R, Greco L, Gianfrani C, La Gruta NL, Anderson RP, Tye-Din JA. Consistency in Polyclonal T-cell Responses to Gluten Between Children and Adults With Celiac Disease. Gastroenterology. 2015 Nov;149(6):1541-1552.e2. PMID: 26226573

Hardy MY, Tye-Din JA, Stewart JA, Schmitz F, Dudek NL, Hanchapola I, Purcell AW, Anderson RP. Ingestion of oats and barley in patients with celiac disease mobilizes cross-reactive T cells activated by avenin peptides and immuno-dominant hordein peptides. J Autoimmun. 2015 Jan;56:56-65. PMID: 25457306

Tye-Din JA, Stewart JA, Dromey JA, Beissbarth T, van Heel DA, Tatham A, Henderson K, Mannering SI, Gianfrani C, Jewell DP, Hill AV, McCluskey J, Rossjohn J, Anderson RP. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2010 Jul 21;2(41):41ra51. PMID: 20650871

Lab research projects

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.